We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Alliance to Develop Test for Prostate Neoplasia

By HospiMedica staff writers
Posted on 19 Jul 2004
Under the terms of a recently announced agreement, GTx, Inc. More...
(Memphis, TN, USA), and diaDexus, Inc. (Santa Clara, CA, USA), will collaborate on developing a commercial assay for blood or urine to detect high-grade prostatic intraepithelial neoplasia (PIN) and/or prostate cancer.

GTx will provide clinical samples from its completed phase IIb clinical trial that evaluated Acapodene (toremifene citrate) tablets for reducing the incidence of prostate cancer in men with high-grade PIN, a malignant lesion with the potential to progress to cancer. Acapodene is a nonsteroidal selective estrogen receptor modulator (SERM) that appears to block the estrogen's unwanted actions on the prostate. The information resulting from this collaboration will be evaluated by diaDexus for the purpose of developing a commercial assay to detect high-grade PIN. Unfortunately, high-grade PIN is currently detected only when men are biopsied.

In the phase IIb trial that evaluated Acapodene, placebo patients had a 31.2% accumulated rate of prostate cancer, while a 20% reduction was seen in the accumulated rate of prostate cancer incidence for patients taking the drug. There was a 46% reduction in prostate cancer incidence for those men who were on Adapodene for the entire year. The placebo patients and the treated patients had similar Gleason scores, indicating that Acapodene is not selecting out more-aggressive tumors. GTx has licensed the right from Orion Corporation (Helsinki, Finland) to develop, market, and distribute toremifene citrate, the active ingredient of Acapodene tablets, worldwide for the prevention and treatment of prostate cancer.

"The development of high-grade PIN could be a component in the recognition and treatment of this disease,” said Mitchell Steiner, M.D., CEO of GTx. "Together with diaDexus, one of the first companies to recognize the potential of genomics to generate valuable diagnostic tests, we have the opportunity to develop products that could have a significant impact in the prevention of prostate cancer.”




Related Links:
GTx
DiaDexus

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.